Il y a eu 50 transactions d'initiés récentes enregistrées pour Olema Pharmaceuticals, Inc. (OLMA), dont 23 achats et 18 ventes. Le total des achats d'initiés s'élève à $24.66M et le total des ventes d'initiés à $15.35M.
Les initiés notables ayant une activité récente comprennent Mitchell Shawnte, Myles David C., Bohen Sean. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — OLMA
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2026-03-04 |
Mitchell Shawnte |
Chief Legal Officer |
Vente Informative |
233 |
$24.69 |
$5.75K |
- |
| 2026-03-03 |
Mitchell Shawnte |
Chief Legal Officer |
Vente Informative |
15,000 |
$23.01 |
$345.15K |
- |
| 2026-02-02 |
Mitchell Shawnte |
Chief Legal Officer |
Attribution de RSU |
56,250 |
$25.65 |
$1.44M |
56,250 |
| 2026-02-02 |
Myles David C. |
Ch. Discov. & Non-clin Dev Off |
Attribution de RSU |
106,250 |
$25.65 |
$2.73M |
106,250 |
| 2026-02-02 |
Bohen Sean |
President and CEO |
Attribution de RSU |
275,000 |
$25.65 |
$7.05M |
275,000 |
| 2026-02-02 |
Zojwalla Naseem |
Chief Medical Officer |
Attribution de RSU |
106,250 |
$25.65 |
$2.73M |
106,250 |
| 2026-02-02 |
Austin Sasha Lu |
VP of Finance and Controller |
Attribution de RSU |
11,700 |
- |
- |
16,188 |
| 2026-02-01 |
Austin Sasha Lu |
VP of Finance and Controller |
Inconnu |
13,000 |
$2.44 |
$31.72K |
- |
| 2026-01-30 |
Austin Sasha Lu |
VP of Finance and Controller |
Inconnu |
45,000 |
$4.37 |
$196.65K |
- |
| 2026-01-20 |
Harmon Cyrus |
Director |
Vente Informative |
10,000 |
$26.88 |
$268.8K |
727,770 |
| 2026-01-15 |
Kovacs Shane William Charles |
Ch. Operating & Financial Off. |
Vente Informative |
100,000 |
$28.73 |
$2.87M |
139,727 |
| 2026-01-14 |
Myles David C. |
Ch. Discov. & Non-clin Dev Off |
Exercice d'Options (Vente) |
50,000 |
$4.87 |
$243.5K |
50,000 |
| 2026-01-14 |
Harmon Cyrus |
Director |
Vente Informative |
3,489 |
$29.12 |
$101.6K |
737,770 |
| 2026-01-13 |
Myles David C. |
Ch. Discov. & Non-clin Dev Off |
Exercice d'Options (Vente) |
50,000 |
$4.87 |
$243.5K |
100,000 |
| 2026-01-13 |
Kovacs Shane William Charles |
Ch. Operating & Financial Off. |
Vente Informative |
3,822 |
$28.01 |
$107.05K |
239,727 |
| 2026-01-12 |
Myles David C. |
Ch. Discov. & Non-clin Dev Off |
Vente Informative |
10,000 |
$28.34 |
$283.4K |
144,846 |
| 2025-12-26 |
Bohen Sean |
President and CEO |
Don (Donné) |
8,500 |
- |
- |
237,650 |
| 2025-12-23 |
Zojwalla Naseem |
Chief Medical Officer |
Vente Informative |
99,509 |
$27.66 |
$2.75M |
4,488 |
| 2025-12-22 |
Zojwalla Naseem |
Chief Medical Officer |
Vente Informative |
100,000 |
$28.04 |
$2.8M |
53,997 |
| 2025-12-22 |
Harmon Cyrus |
Director |
Vente Informative |
2,881 |
$28.53 |
$82.19K |
741,259 |
| 2025-12-19 |
Clark Ian T |
Director |
Exercice d'Options (Vente) |
21,520 |
$3.61 |
$77.69K |
- |
| 2025-12-19 |
Myles David C. |
Ch. Discov. & Non-clin Dev Off |
Don (Donné) |
9,000 |
- |
- |
542,881 |
| 2025-12-19 |
Zojwalla Naseem |
Chief Medical Officer |
Vente Informative |
12,921 |
$28.93 |
$373.8K |
103,997 |
| 2025-12-08 |
Kovacs Shane William Charles |
Ch. Operating & Financial Off. |
Don (Donné) |
75,000 |
- |
- |
243,549 |
| 2025-11-26 |
Kovacs Shane William Charles |
Ch. Operating & Financial Off. |
Don (Donné) |
225,000 |
- |
- |
318,549 |
| 2025-11-25 |
Rappaport Andrew |
Director |
Don (Donné) |
35,868 |
- |
- |
- |
| 2025-11-21 |
Rappaport Andrew |
Director |
Exercice d'Options (Vente) |
35,868 |
$0.39 |
$13.99K |
- |
| 2025-09-18 |
Harmon Cyrus |
Director |
Vente Informative |
3,086 |
$8.32 |
$25.68K |
117,028 |
| 2025-09-16 |
Harmon Cyrus |
Director |
Vente Informative |
1,914 |
$8.08 |
$15.47K |
120,114 |
| 2025-06-11 |
Bvf Partners L P/il |
Other: See Explanation of Responses |
Attribution de RSU |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Rappaport Andrew |
Director |
Attribution de RSU |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Butitta Cynthia M |
Director |
Attribution de RSU |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Clark Ian T |
Director |
Attribution de RSU |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Garland J. Scott |
Director |
Attribution de RSU |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Horning Sandra |
Director |
Attribution de RSU |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Graham G. Walmsley |
Director |
Attribution de RSU |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Larson Yi |
Director |
Attribution de RSU |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Hrustanovic Gorjan |
Director |
Attribution de RSU |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Harmon Cyrus |
Director |
Attribution de RSU |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-02-28 |
Kovacs Shane William Charles |
Ch. Operating & Financial Off. |
Attribution de RSU |
320,000 |
$4.37 |
$1.4M |
320,000 |
| 2025-02-28 |
Mitchell Shawnte |
Chief Legal Officer |
Attribution de RSU |
450,000 |
$4.37 |
$1.97M |
450,000 |
| 2025-02-28 |
Myles David C. |
Ch. Discov. & Non-clin Dev Off |
Attribution de RSU |
205,000 |
$4.37 |
$895.85K |
205,000 |
| 2025-02-28 |
Bohen Sean |
President and CEO |
Attribution de RSU |
650,000 |
$4.37 |
$2.84M |
650,000 |
| 2025-02-28 |
Zojwalla Naseem |
Chief Medical Officer |
Attribution de RSU |
205,000 |
$4.37 |
$895.85K |
205,000 |
| 2025-02-18 |
Mitchell Shawnte |
Officer |
Inconnu |
- |
- |
- |
- |
| 2025-01-10 |
Bain Capital Life Sciences Investors, Llc |
10 Percent Owner |
Autre (Achat) |
3,500,000 |
$0.00 |
$350.00 |
3,500,000 |
| 2025-01-10 |
Bvf Partners L P/il |
Other: See Explanation of Responses |
Attribution de RSU |
22,740 |
$0.00 |
$2.27 |
336,288 |
| 2025-01-08 |
Bain Capital Life Sciences Investors, Llc |
10 Percent Owner |
Inconnu |
- |
- |
- |
7,500,000 |
| 2025-01-08 |
Bain Capital Life Sciences Investors, Llc |
10 Percent Owner |
Achat Informatif |
300,000 |
$5.76 |
$1.73M |
7,800,000 |
| 2024-12-17 |
Graham G. Walmsley |
Director |
Vente Informative |
700,761 |
$6.75 |
$4.73M |
- |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
